OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)

被引：0
|
作者：
Negrier, S. [1 ]
Figlin, R. A. [2 ]
Hutson, T. E. [3 ]
Tomczak, P. [4 ]
Michaelson, M. D. [5 ]
Bukowski, R. M. [6 ]
Huang, X. [7 ]
Kim, S. T. [7 ]
Chen, I. [7 ]
Motzer, R. J. [8 ]
机构：
[1] Ctr Leon Berard, Cytokines & Canc Res Unit, F-69373 Lyon, France
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Baylor Sammons Texas Oncol PA, Dallas, TX USA
[4] Klin Onkol Oddzial Chernioterapii, Poznan, Poland
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
[7] Pfizer Inc, Global Res & Dev, La Jolla, CA USA
[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [21] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Phase III randomized trial of sunitinib malate (SU1 1248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC).
    Motzer, R. J.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Rixe, O.
    Oudard, S.
    Kim, S. T.
    Baum, C. M.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2S - 2S
  • [23] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Wells, J. Connor
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Brugarolas, James
    Broom, Reuben James
    Bamias, Aristotelis
    Yuasa, Takeshi
    Srinivas, Sandhya
    Ernst, D. Scott
    Pezaro, Carmel Jo
    Wood, Lori
    Kollmannsberger, Christian K.
    Rini, Brian I.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Hutson, Thomas E.
    Tomczak, Piotr
    Michaelson, M. Dror
    Bukowski, Ronald M.
    Oudard, Stephane
    Negrier, Sylvie
    Szczylik, Cezary
    Pili, Roberto
    Bjarnason, Georg A.
    Garcia-del-Muro, Xavier
    Sosman, Jeffrey A.
    Solska, Ewa
    Wilding, George
    Thompson, John A.
    Kim, Sindy T.
    Chen, Isan
    Huang, Xin
    Figlin, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3584 - 3590
  • [25] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [27] A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone
    Kollmannsberger, C. K.
    Heng, D. Y.
    Murray, N.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
    Vuorinen, Riikka-Liisa
    Paunu, Niina
    Turpeenniemi-Hujanen, Taina
    Reunamo, Taina
    Jekunen, Antti
    Kataja, Vesa
    Sintonen, Harri
    Purmonen, Timo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2019, 39 (10) : 5559 - 5564
  • [29] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
    Benedict, A.
    Figlin, R. A.
    Charbonneau, C.
    Kreif, N.
    Hariharan, S.
    Negrier, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN).
    Blagoev, K. B.
    Wilkerson, J.
    Stein, W. D.
    Motzer, R. J.
    Bates, S. E.
    Fojo, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345